Cited by 142Liver Disease Diagnosis and TreatmentFatty Acid Research and HealthAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease

Open access

Jump, Donald B., Lytle, Kelli A., Depner, Christopher M., Tripathy, Sasmita·2018·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2017.07.007PMC PMC5743581

Open this paper in CoChat — free account

Abstract

Obese and type 2 diabetic (T2DM) patients have a high prevalence of nonalcoholic fatty liver disease (NAFLD). NAFLD is a continuum of chronic liver diseases ranging from benign hepatosteatosis to nonalcoholic steatohepatitis (NASH), cirrhosis and primary hepatocellular cancer (HCC). Because of its strong association with the obesity epidemic, NAFLD is rapidly becoming a major public health concern worldwide. Surprisingly, there are no FDA approved NAFLD therapies; and current therapies focus on the co-morbidities associated with NAFLD, namely, obesity, hyperglycemia, dyslipidemia, and hypertension. The goal of this review is to provide background on the disease process, discuss human studies and preclinical models that have examined treatment options. We also provide an in-depth rationale for the use of dietary ω3 polyunsaturated fatty acid (ω3 PUFA) supplements as a treatment option for NAFLD. This focus is based on recent studies indicating that NASH patients and preclinical mouse models of NASH have low levels of hepatic C 20-22 ω3 PUFA. This decline in hepatic PUFA may account for the major phenotypic features associated with NASH, including steatosis, inflammation and fibrosis. Finally, our discussion will address the strengths and limitations of ω3 PUFA supplements use in NAFLD therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2017.07.007

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
The importance of the ratio of omega-6/omega-3 essential fatty acids
Simopoulos, A. P. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(02)00253-6 · Cited by 4,286
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Hepatocellular carcinoma
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,083
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
Funk, C. D. (2001) · Science · doi:10.1126/science.294.5548.1871 · Cited by 3,817

Flagged first, then by citations

Show all 218 references

2 of the 218 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–142 of 142

Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH
Sobhia, M. E., Kumari, S., Kumar, H., Gandhe, A., Kaushik, D., Kumar, H., Jain, J., Ankita, A., Mallick, M., Pavani, B., et al. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230714113808 · Cited by 4
Dietary Omega-3 Fatty Acids from Fish and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Mediterranean Population: Findings from the NUTRIHEP Cohort
Tatoli, R., Bonfiglio, C., Donghia, R., Pesole, P. L., Fontana, L., & Giannelli, G. (2025) · Nutrients · doi:10.3390/nu17213372 · Cited by 5
Is any association between alternate healthy eating index (AHEI) with lipid profile and liver enzymes? A cross-sectional Study
Mirashrafi, S., Kafeshani, M., Hassanzadeh, A., & Entezari, M. H. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00898-w · Cited by 4
The effect of omega-3 supplementation on glycemic indices and lipid profile in type 2 diabetic patients with non-alcoholic fatty liver disease: A double-blind, randomized, clinical trial
Orang, Z., Mozaffari–Khosravi, H., Sivandzadeh, G., & Pantović, A. (2019) · Mediterranean Journal of Nutrition and Metabolism · doi:10.3233/mnm-180265 · Cited by 4
Modern Management of Patients with Nonalcoholic Fatty Liver Disease
Tsukanov, V. V., Vasyutin, A. V., & Tonkikh, Y. L. (2019) · Doctor Ru · doi:10.31550/1727-2378-2019-158-3-11-14 · Cited by 4
Polyunsaturated fatty acids: omega-3 and omega-6 and nonalcoholic fatty liver disease
Berezhnaya, I. V., Zakharova, I. N., Simakova, M. A., & Sgibneva, A. I. (2021) · Pediatrics Consilium Medicum · doi:10.26442/26586630.2021.4.201348 · Cited by 4
Are marine n-3 fatty acids protective towards insulin resistance? From cell to human
Delarue, J. (2020) · Proceedings of The Nutrition Society · doi:10.1017/s0029665120000087 · Cited by 4
Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study
Takeda, Y., Furuhashi, M., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., Kumashiro, N., & Sakurai, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1549687 · Cited by 3
Omega-3 polyunsaturated fatty acids for the management of dyslipidemia and reduction of residual cardiovascular risk
Kytikovа, O. Y., Novgorodtseva, T. P., Denisenko, Y., Antonyuk, M. V., & Gvozdenko, T. A. (2023) · Bulletin physiology and pathology of respiration · doi:10.36604/1998-5029-2023-87-124-137 · Cited by 3
Identification of hub genes and small molecule therapeutic drugs related to simple steatosis with secondary analysis of existing microarray data
Mao, Y.-J., Ying, M., & Xu, G. (2022) · All Life · doi:10.1080/26895293.2022.2114550 · Cited by 2
Az ómega-3 zsírsavak jelentősége a nem alkoholos zsírmájbetegség kezelésében
Makó, R. A., Egresi, A., Blázovics, A., Oszlányi, R., & Hagymási, K. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32834 · Cited by 2
The Curative and Preventative Effects of Traditional Chinese Medicine on Ferroptosis of Hepatocellular Carcinoma
Peng, W., Yang, R., Li, K., Jian, X., & Zeng, P. (2023) · Natural Product Communications · doi:10.1177/1934578x231220485 · Cited by 2
The Dietary Pattern Concerning Non-alcoholic Fatty Liver: An Umbrella Review and Meta-analyses of Observational Studies and Intervention Trials
Moradi, S., Saber, A., Moradinazar, M., Heydarian, A., Cheshmeh, S., Sadeghi, F., & Pasdar, Y. (2024) · Journal of Kermanshah University of Medical Sciences · doi:10.5812/jkums-142759 · Cited by 1
Identification of trait-associated microRNA modules in liver transcriptome of pig fed with PUFAs-enriched supplementary diet
Pareek, C. S., Sachajko, M., Kalra, G., Sultana, S., Szostak, A., Chałaśkiewicz, K., Kępka-Borkowska, K., Poławska, E., Ogłuszka, M., Pierzchała, D., et al. (2024) · Journal of Applied Genetics · doi:10.1007/s13353-024-00912-w · Cited by 1
Fatty acid profile, lipid indices and lipid peroxidation in chicken meat: the effect of dietary vegetable oils and vitamin C/selenium supplement
Shurmasti, D. K., Shariatmadari, F., Lima, C. M. G., & Coutinho, H. D. M. (2025) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.70130 · Cited by 1
Protective Effects of Neutral Lipids from Phaeodactylum tricornutum on Palmitate-Induced Lipid Accumulation in HepG2 Cells: An In Vitro Model of Non-Alcoholic Fatty Liver Disease
Peyras, M., Orhant, R.-M., Parisi, G., Faraloni, C., Zittelli, G. C., Blanckaert, V. D., & Mimouni, V. (2026) · Molecules · doi:10.3390/molecules31020323 · Cited by 1
Octopus (Enterocopus dofleini) Liver Extract Displays Triglyceride-Lowering Effect in HepG2 Cells
Hasegawa, Y. (2017) · Agriculture Forestry and Fisheries · doi:10.11648/j.aff.20170606.15 · Cited by 1
Non-Alcoholic Fatty Liver Disease: Bases for Therapeutic Roles of Vitamin E and n-3 PUFA
Rodrigo, R. (2017) · Journal of Liver Research Disorders & Therapy · doi:10.15406/jlrdt.2017.03.00079 · Cited by 1
Análisis del contenido de ácidos grasos y estimación de índices de calidad nutricional en conservas de atún
Cifuentes, C., & Rincón‐Cervera, M. Á. (2022) · Revista chilena de nutrición · doi:10.4067/s0717-75182022000600588 · Cited by 1
Hepatoprotective effect of MUFA-enriched refined Greenland halibut fin oil to inhibit hepatic fibrosis in carbon tetrachloride-induced mice
Sun, P.-P., Tseng, Y.-S., Chen, C., Lai, C., Dong, C., Sharma, V., & Tsai, M.-L. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.105475 · Cited by 1
Nutritive Value and Quality of Sweet Basil Leaves in an Animal Model of Nonalcoholic Fatty Liver Disease
El-Hashash, S. A. (2019) · Egyptian Journal of Food Science · doi:10.21608/ejfs.2019.13898.1011 · Cited by 1
Bioactive lipids in metabolic liver disease
Morales-Olvera, C. G., Sánchez-Pérez, C. A., Barbero-Becerra, V. J., Juárez-Hernández, E., Uribe, M., & Chávez-Tapia, N. C. (2021) · Studies in natural products chemistry · doi:10.1016/b978-0-12-819487-4.00005-7 · Cited by 1
The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status
Li, L., Cong, C., Zhang, X., & Zhang, X. (2026) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s573711
“9,10 13 This inconsistency obscures the true therapeutic value of omega-3 polyunsaturated fatty acids and suggests the presence of key effect-modifying factors.”
Effet des acides gras polyinsaturés à longue chaîne n-3 sur le remodelage membranaire induit par les toxiques chimiques : retentissement sur la mort cellulaire
Sergent, O., Podechard, N., & Lagadic‐Gossmann, D. (2018) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2018.11.001
Modern Principles of Management of Patients with Non-Alcoholic Fatty Liver Disease
Rakhmatjanovna, U. S., Malikovich, R. S., & Naimovna, S. G. (2020) · American Journal of Medicine and Medical Sciences
Rock1-Ppp1cb-Ampk Signaling Axis: A Novel Therapeutic Pathway of Quercetin, the Bioactive Component of Hawk Tea to Ameliorate NafldPreprint
Feng, J., Li, W., Hong, J., Weng, Q., Qiao, L., Zheng, Y., & Li, L. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4628142
Lipid-rich biomass
Ghalamara, S., Salsinha, A. S., Ujong, A., Pintado, M., & Tiwari, B. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28810-4.00018-9
Modern aspects of management of patients with metabolic dysfunction-associated steatotic liver disease
Tsukanov, V. V., Vasyutin, A. V., & Tonkikh, Y. L. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-342
Docosahexaenoic acid (DHA) alleviates hepatic lipid deposition in dairy cows during the transition period: an integrated in vitro and in vivo study
Zhang, X., Liu, X., Liu, S., Tang, W., Ji, S., Ji, H., Wang, Y. J., Cao, Z., Yang, H., Wang, W., et al. (2025) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-025-01308-4
Additional file 1 of Si-Wu-Tang alleviates metabolic dysfunction-associated fatty liver disease by inhibiting ACSL4-mediated arachidonic acid metabolism and ferroptosis in MCD diet-fed mice
Xue, X., Wang, L., Wu, R., Li, Y., Liu, R., Ma, Z., Jia, K., Zhang, Y., & Li, X. (2024) · Figshare · doi:10.6084/m9.figshare.26730670
Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction–associated steatotic liver disease and its progression to hepatocellular carcinoma
Kouti, T., Christodoulou, P., Christodoulides, S., Protopapa, F., Michaeloudes, C., & Farazi, P. A. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1767917
Étude des effets d’un régime supplémenté en vitamine D et en acides gras oméga-3 dans la prévention tertiaire des altérations métaboliques et fonctionnelles associées à l’obésité chez le Rat Wistar
Jan, D. L. (2024) · theses.fr (ABES) · doi:10.70675/044ae8ecz4971z4637zb911z4a21f0b27e28
Health benefit considerations for the development of fish advisory guidelines for PFOS
Spliethoff, H. M., Palmer, M. C., Marquez‐Bravo, L. G., Marks, T., & Ginsberg, G. (2026) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2026.2665431 · Cited by 1
The effect of vitamin D supplementation on the liver function in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis of randomized controlled trials
Vajdi, M., Nikrad, N., Khajeh, M., Noshadi, N., Maroofi, M., Darzi, M., Tabrizi, F. P. F., & Askari, G. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02225-w
Nutritional Optimization
González-Ramos, M. (2026) · Springer eBooks · doi:10.1007/978-3-032-25644-7_3
Impacts on noninfectious diseases
Hewage, S. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29190-6.10015-7
Metabolomic Profiles Predict the Risk of Idiopathic Pulmonary Fibrosis
Xie, Y., Yang, S., You, X., Yin, H., Shang, B., Liu, H., Yao, Y., Zhou, C., Ji, X., & Ma, J. (2026) · Phenomics · doi:10.1007/s43657-025-00268-z
Loss of dmrt2a Alters Hepatic LC-PUFA Composition and Lipid Homeostasis in Zebrafish
Hou, M., Li, D., ZHANG, Y., & Hengde, L. I. (2026) · Cells · doi:10.3390/cells15191763
Mechanistic insights into the therapeutic effects of Mongolian medicine Eligengurigumu-7 against non-alcoholic fatty liver disease via the PPAR signalling pathway
Huang, C., Wu, H., Zhang, S., Feng, W., Liu, Z., Hua, C., Chen, D., Han, G., Gao, Y., 张恒辉, et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158846
Effects of black cumin, linseed, and putty fish oils on dyslipidemia and hepatic enzyme activities in high-fat diet-induced obese wistar rats
Linkon, K. M. M. R., Hossain, M. A., Khatun, E., Saha, R. K., Rahman, M. L., Akter, P., Akter, R., Amin, A., Akter, M. T., Noman, A. A., et al. (2026) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2026.100748
Temporal Changes in Hepatic Fatty Acid Metabolism, Desaturase Expression, and Lipid Peroxidation During Long-Term Sucrose Feeding in Male and Female Rats
Heštera, S., Mašek, T., Roginek, P., Maljković, M. M., Micek, V., & Starčević, K. (2026) · Metabolites · doi:10.3390/metabo16110827
Hormonal and metabolic adaptations in Omega-3-supplemented rabbit does during their first reproductive cycle
Quattrone, A., Fehri, N. E., Barbato, O., Ricci, G., Vigo, D., Turmalaj, L., Sulçe, M., Castrica, M., Marongiu, M. L., Bosco, A. D., et al. (2026) · Veterinary Quarterly · doi:10.1080/01652176.2026.2749322

Authors: Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S.
Affiliations: Oregon State University (US)
ORCID: Lytle, Kelli A.
Depner, Christopher M.
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2018-01
Volume: 181
Pages: 108-125
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2017.07.007
PMC: PMC5743581
OpenAlex: W2735867008
Cited by: 142
References: 218
Citations by year: 2026: 13 · 2025: 8 · 2024: 20 · 2023: 21 · 2022: 14 · 2021: 18 · 2020: 23 · 2019: 12 · 2018: 11
FWCI: 1.74
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (am, 355 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Pharmacology & Therapeutics (acceptedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Food and Agriculture (2009-65200-05846)
National Institutes of Health (DK 094600)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: omega-3 polyunsaturated fatty acids, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, dietary supplementation, hepatic steatosis, liver fibrosis, liver inflammation, obesity, type 2 diabetes
MeSH terms: Animals, Disease Models, Animal, Humans, Fatty Acids, Omega-3, Disease Progression, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks